Vir Biotechnology, Inc. splits its revenue into 8 lines in its filings. The largest line in fiscal 2025, which ended Dec 31, 2025 was License And Collaboration Revenue at $63.1 million, 92% of the total.
USD in millions. The percent under a figure is the change from the year before.
| Line |
FY 2026
Sep 30, 2026
|
FY 2025
Dec 31, 2025
|
FY 2024
Dec 31, 2024
|
FY 2023
Dec 31, 2023
|
FY 2022
Dec 31, 2022
|
FY 2021
Dec 31, 2021
|
FY 2020
Dec 31, 2020
|
FY 2019
Dec 31, 2019
|
|---|---|---|---|---|---|---|---|---|
| Revenue |
303
|
69
|
74
|
86
|
1,616
|
1,095
|
76
|
8
|
| License And Collaboration Revenue |
—
|
63
+2.9%
share 92.1%
|
61
+64.2%
share 82.7%
|
37
share 43.4%
|
—
|
917
share 83.7%
|
—
|
—
|
| Profit Sharing Amount Previously Constrained Released |
—
|
—
|
—
|
36
share 41.4%
|
—
|
—
|
—
|
—
|
| License |
—
|
—
|
—
|
—
|
—
|
—
|
23
share 29.8%
|
—
|
| License Revenue |
—
|
—
|
—
|
—
|
22
share 1.4%
|
—
|
—
|
—
|
| Other Revenue |
—
|
3
+44.7%
share 4.9%
|
2
+10.9%
share 3.2%
|
2
-96.0%
share 2.5%
|
53
-69.0%
share 3.3%
|
170
+281.8%
share 15.5%
|
44
+6158.5%
share 58.3%
|
1
share 8.8%
|
| Grant |
—
|
2
-80.6%
share 3.0%
|
10
-77.5%
share 14.1%
|
47
+32.2%
share 54.2%
|
35
+323.2%
share 2.2%
|
8
share 0.8%
|
—
|
—
|
| Profit Sharing Amount Constrained |
—
|
—
|
-1
share -0.9%
|
—
|
-370
share -22.9%
|
—
|
—
|
—
|
| Profit Sharing Amount |
—
|
-1
-112.5%
share -1.7%
|
9
+491.0%
share 12.2%
|
2
-99.9%
share 1.8%
|
1,875
+104.4%
share 116.1%
|
917
share 83.7%
|
—
|
—
|
How these figures are calculated
Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions. Each group is a separate split of total revenue, so the groups are not added together. Share of revenue is that line divided by total revenue. The first column adds the latest year-to-date segment amount to the last fiscal year and subtracts the year-ago year-to-date amount. More on our methodology.
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- VIR (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- San Francisco, CA
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1706431
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.